ArticleFrontiers in immunology2023

The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma.

Hui Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.